pipeline

ABL Bio is the first biotech company in Korea with a bispecific antibody platform that is undergoing clinical trial.

  • CNS Disease
    A bispecific antibody platform with robust penetrative ability through the blood-brain-barrier (BBB) as a treatment to various neurodegenerative diseases
    The Grabody B platform targets insulin-like growth factor 1 receptor (IGF1R) to function as a BBB shuttle
  • IMMUNO-ONCOLOGY
    Bispecific antibody to address current limitations of PD-(L)1 checkpoint inhibitors
    Minimize the systemic toxicity associated with 4-1BB based immunotherapy, increase low reponse rates and overcome the resistance observed with traditional PD-(L)1 therapy
  • ADC
    Developing antibody drug conjugates (ADC) with an improved therapy index
    Challenging the development of rare blood cancer treatments with ADC drug candidates that have better in vivo pharmacokinetic parameters

MORE

INVESTOR RELATIONS

Information on ABL Bio's IR

career

ABL Bio History

ABL Bio

2022

  • 05

    Article about ABL501 published in Molecular Therapy

  • 03

    ABL111 received Orphan-Drug Designation

  • 01

    Signs licensing agreement with Sanofi

2021

  • 12

    re-certified as Korea Innovative Pharmaceutical Company

  • 08

    ABL501 Phase 1 clinical trial IND approved by MFDS

  • 07

    Review paper on bispecific antibody-based immunotherapy published in Vaccines

  • 06

    First patient dosed in Phase 1 clinical trial in of ABL111

  • 04

    First patient dosed in Phase 1 clinical trial of ABL503

  • 03

    ABL111 phase 1 clinical trial IND approved by U.S. FDA

  • 02

    ABL001 Phase 1 clinical trial IND approved by MFDS

  • 01

    ABL503 Phase 1 clinical trial IND approved by U.S. FDA

  • 01

    ABL's 4-1BB bispecific antibody introduced in 'Science Advances'

  • 01

    ABL001 research published in International Journal of Molecular Sciences

MORE